During CD22 CAR-T therapy, grade 3 or 4 lymphocytopenia occurred in all patients, neutropenia in 87.0%, anemia in 21.7%, and thrombocytopenia in 52.2%. This evidence concerns the gene CD22 and anemia (phenotype).